GlassScriptPhysician profile
Lampros Papadimitriou
NPI 1205322385
$8,690.86
in general payments reported to CMS, 2019-2025
38 companies · $881 in 2025
The $881 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,012 · 2020: $1,452 · 2021: $763 · 2022: $1,585 · 2023: $1,249 · 2024: $748 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,868 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,868.29 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,221.16 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Merck Sharp & Dohme LLC | $1,166.55 | 2019-2025 | Verquvo, Winrevair |
| Pfizer INC. | $830.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $712.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.47 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $520.30 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $461.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $376.05 | 2019-2024 | Xarelto |
| Vifor Pharma, INC. | $367.61 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $352.62 | 2020-2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $348.64 | 2019-2025 | Farxiga, Wainua, Brilinta |
| United Therapeutics Corporation | $174.56 | 2019-2025 | Tyvaso, Tyvaso |
| Irhythm Technologies, INC. | $162.60 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $150.46 | 2023-2025 | Watchman Access System |
| Daxor Corporation | $129.58 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $119.48 | 2021-2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $118.63 | 2019-2023 | |
| Astellas Pharma US INC | $109.52 | 2019-2020 | |
| Inspire Medical Systems, INC. | $87.39 | 2024-2025 | Inspire |
| Amgen INC. | $74.20 | 2020-2022 | |
| Braemar Manufacturing, LLC | $72.77 | 2019 | |
| Alnylam Pharmaceuticals INC. | $61.03 | 2025 | Amvuttra |
| Livanova USA, INC. | $58.26 | 2022-2023 | Tandemlife |
| Lexicon Pharmaceuticals, INC. | $52.82 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $49.30 | 2025 | Evkeeza |
| Akcea Therapeutics, INC. | $43.85 | 2019-2020 | |
| Medtronic, INC. | $32.15 | 2021-2024 | |
| Cvrx, INC. | $31.07 | 2023 | Barostim Neo System |
| Novo Nordisk INC | $30.88 | 2025 | Wegovy |
| Scpharmaceuticals INC. | $30.43 | 2024 | |
| Philips North America LLC | $26.49 | 2024 | (Cm9) Amb Mon & Diag Und |
| Medtronic Vascular, INC. | $25.21 | 2020 | |
| Bridgebio Pharma, INC. | $21.53 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $13.93 | 2024 | Sapien 3 Ultra Resilia |
| Chiesi USA, INC. | $13.63 | 2024 | Juxtapid |
| Ge Healthcare | $11.56 | 2019 | |
| Nuwellis, INC. | $10.78 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lampros Papadimitriou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.